The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Drugs of UDCA-Global Market Insights and Sales Trends 2024
Synopsis
The drug decreases the absorption of cholesterol and is used to dissolve (cholesterol) gallstones in patients as an alternative to a surgical procedure to remove the gallstones.
The global Drugs of UDCA market size is expected to reach US$ 3389.8 million by 2029, growing at a CAGR of 10.7% from 2023 to 2029. The market is mainly driven by the significant applications of Drugs of UDCA in various end use industries. The expanding demands from the Gallstone, Hepatopathy, Biliary Disease and Other, are propelling Drugs of UDCA market. Capsule, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Tablet segment is estimated at % CAGR for the next seven-year period.
UDCA is a bile acid used in the treatment of various liver disorders, such as primary biliary cholangitis and primary sclerosing cholangitis. The increasing prevalence of these liver diseases, along with growing awareness about their diagnosis and treatment, is driving market growth. Additionally, advancements in drug formulations, such as the development of extended-release and combination therapies, are further contributing to market expansion. The market is highly competitive, with several pharmaceutical companies actively engaged in the production and distribution of UDCA drugs. However, challenges such as high drug costs, side effects, and limited accessibility in certain regions may hinder market growth.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drugs of UDCA, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drugs of UDCA market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drugs of UDCA market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drugs of UDCA sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drugs of UDCA covered in this report include Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Mylan, Bruschettini and Impax, etc.
The global Drugs of UDCA market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Global Drugs of UDCA market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drugs of UDCA market, Segment by Type:
Capsule
Tablet
Global Drugs of UDCA market, by Application
Gallstone
Hepatopathy
Biliary Disease
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Drugs of UDCA manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Drugs of UDCA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The drug decreases the absorption of cholesterol and is used to dissolve (cholesterol) gallstones in patients as an alternative to a surgical procedure to remove the gallstones.
The global Drugs of UDCA market size is expected to reach US$ 3389.8 million by 2029, growing at a CAGR of 10.7% from 2023 to 2029. The market is mainly driven by the significant applications of Drugs of UDCA in various end use industries. The expanding demands from the Gallstone, Hepatopathy, Biliary Disease and Other, are propelling Drugs of UDCA market. Capsule, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Tablet segment is estimated at % CAGR for the next seven-year period.
UDCA is a bile acid used in the treatment of various liver disorders, such as primary biliary cholangitis and primary sclerosing cholangitis. The increasing prevalence of these liver diseases, along with growing awareness about their diagnosis and treatment, is driving market growth. Additionally, advancements in drug formulations, such as the development of extended-release and combination therapies, are further contributing to market expansion. The market is highly competitive, with several pharmaceutical companies actively engaged in the production and distribution of UDCA drugs. However, challenges such as high drug costs, side effects, and limited accessibility in certain regions may hinder market growth.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drugs of UDCA, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drugs of UDCA market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drugs of UDCA market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drugs of UDCA sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drugs of UDCA covered in this report include Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Mylan, Bruschettini and Impax, etc.
The global Drugs of UDCA market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Global Drugs of UDCA market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drugs of UDCA market, Segment by Type:
Capsule
Tablet
Global Drugs of UDCA market, by Application
Gallstone
Hepatopathy
Biliary Disease
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Drugs of UDCA manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Drugs of UDCA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Drugs of UDCA Market Overview
1.1 Drugs of UDCA Product Overview
1.2 Drugs of UDCA Market Segment by Type
1.2.1 Capsule
1.2.2 Tablet
1.3 Global Drugs of UDCA Market Size by Type
1.3.1 Global Drugs of UDCA Market Size Overview by Type (2018-2029)
1.3.2 Global Drugs of UDCA Historic Market Size Review by Type (2018-2023)
1.3.3 Global Drugs of UDCA Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Drugs of UDCA Sales Breakdown by Type (2018-2023)
1.4.2 Europe Drugs of UDCA Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Drugs of UDCA Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Drugs of UDCA Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Drugs of UDCA Sales Breakdown by Type (2018-2023)
2 Global Drugs of UDCA Market Competition by Company
2.1 Global Top Players by Drugs of UDCA Sales (2018-2023)
2.2 Global Top Players by Drugs of UDCA Revenue (2018-2023)
2.3 Global Top Players by Drugs of UDCA Price (2018-2023)
2.4 Global Top Manufacturers Drugs of UDCA Manufacturing Base Distribution, Sales Area, Product Type
2.5 Drugs of UDCA Market Competitive Situation and Trends
2.5.1 Drugs of UDCA Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Drugs of UDCA Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Drugs of UDCA as of 2022)
2.7 Date of Key Manufacturers Enter into Drugs of UDCA Market
2.8 Key Manufacturers Drugs of UDCA Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Drugs of UDCA Status and Outlook by Region
3.1 Global Drugs of UDCA Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Drugs of UDCA Historic Market Size by Region
3.2.1 Global Drugs of UDCA Sales in Volume by Region (2018-2023)
3.2.2 Global Drugs of UDCA Sales in Value by Region (2018-2023)
3.2.3 Global Drugs of UDCA Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Drugs of UDCA Forecasted Market Size by Region
3.3.1 Global Drugs of UDCA Sales in Volume by Region (2024-2029)
3.3.2 Global Drugs of UDCA Sales in Value by Region (2024-2029)
3.3.3 Global Drugs of UDCA Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Drugs of UDCA by Application
4.1 Drugs of UDCA Market Segment by Application
4.1.1 Gallstone
4.1.2 Hepatopathy
4.1.3 Biliary Disease
4.1.4 Other
4.2 Global Drugs of UDCA Market Size by Application
4.2.1 Global Drugs of UDCA Market Size Overview by Application (2018-2029)
4.2.2 Global Drugs of UDCA Historic Market Size Review by Application (2018-2023)
4.2.3 Global Drugs of UDCA Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Drugs of UDCA Sales Breakdown by Application (2018-2023)
4.3.2 Europe Drugs of UDCA Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Drugs of UDCA Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Drugs of UDCA Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Drugs of UDCA Sales Breakdown by Application (2018-2023)
5 North America Drugs of UDCA by Country
5.1 North America Drugs of UDCA Historic Market Size by Country
5.1.1 North America Drugs of UDCA Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Drugs of UDCA Sales in Volume by Country (2018-2023)
5.1.3 North America Drugs of UDCA Sales in Value by Country (2018-2023)
5.2 North America Drugs of UDCA Forecasted Market Size by Country
5.2.1 North America Drugs of UDCA Sales in Volume by Country (2024-2029)
5.2.2 North America Drugs of UDCA Sales in Value by Country (2024-2029)
6 Europe Drugs of UDCA by Country
6.1 Europe Drugs of UDCA Historic Market Size by Country
6.1.1 Europe Drugs of UDCA Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Drugs of UDCA Sales in Volume by Country (2018-2023)
6.1.3 Europe Drugs of UDCA Sales in Value by Country (2018-2023)
6.2 Europe Drugs of UDCA Forecasted Market Size by Country
6.2.1 Europe Drugs of UDCA Sales in Volume by Country (2024-2029)
6.2.2 Europe Drugs of UDCA Sales in Value by Country (2024-2029)
7 Asia-Pacific Drugs of UDCA by Region
7.1 Asia-Pacific Drugs of UDCA Historic Market Size by Region
7.1.1 Asia-Pacific Drugs of UDCA Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Drugs of UDCA Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Drugs of UDCA Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Drugs of UDCA Forecasted Market Size by Region
7.2.1 Asia-Pacific Drugs of UDCA Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Drugs of UDCA Sales in Value by Region (2024-2029)
8 Latin America Drugs of UDCA by Country
8.1 Latin America Drugs of UDCA Historic Market Size by Country
8.1.1 Latin America Drugs of UDCA Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Drugs of UDCA Sales in Volume by Country (2018-2023)
8.1.3 Latin America Drugs of UDCA Sales in Value by Country (2018-2023)
8.2 Latin America Drugs of UDCA Forecasted Market Size by Country
8.2.1 Latin America Drugs of UDCA Sales in Volume by Country (2024-2029)
8.2.2 Latin America Drugs of UDCA Sales in Value by Country (2024-2029)
9 Middle East and Africa Drugs of UDCA by Country
9.1 Middle East and Africa Drugs of UDCA Historic Market Size by Country
9.1.1 Middle East and Africa Drugs of UDCA Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Drugs of UDCA Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Drugs of UDCA Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Drugs of UDCA Forecasted Market Size by Country
9.2.1 Middle East and Africa Drugs of UDCA Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Drugs of UDCA Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Dr. Falk Pharma
10.1.1 Dr. Falk Pharma Company Information
10.1.2 Dr. Falk Pharma Introduction and Business Overview
10.1.3 Dr. Falk Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Dr. Falk Pharma Drugs of UDCA Products Offered
10.1.5 Dr. Falk Pharma Recent Development
10.2 Daewoong Pharmaceutical
10.2.1 Daewoong Pharmaceutical Company Information
10.2.2 Daewoong Pharmaceutical Introduction and Business Overview
10.2.3 Daewoong Pharmaceutical Drugs of UDCA Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Daewoong Pharmaceutical Drugs of UDCA Products Offered
10.2.5 Daewoong Pharmaceutical Recent Development
10.3 Teva
10.3.1 Teva Company Information
10.3.2 Teva Introduction and Business Overview
10.3.3 Teva Drugs of UDCA Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Teva Drugs of UDCA Products Offered
10.3.5 Teva Recent Development
10.4 Epic Pharma
10.4.1 Epic Pharma Company Information
10.4.2 Epic Pharma Introduction and Business Overview
10.4.3 Epic Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Epic Pharma Drugs of UDCA Products Offered
10.4.5 Epic Pharma Recent Development
10.5 Mitsubishi Tanabe Pharma
10.5.1 Mitsubishi Tanabe Pharma Company Information
10.5.2 Mitsubishi Tanabe Pharma Introduction and Business Overview
10.5.3 Mitsubishi Tanabe Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Mitsubishi Tanabe Pharma Drugs of UDCA Products Offered
10.5.5 Mitsubishi Tanabe Pharma Recent Development
10.6 Lannett
10.6.1 Lannett Company Information
10.6.2 Lannett Introduction and Business Overview
10.6.3 Lannett Drugs of UDCA Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Lannett Drugs of UDCA Products Offered
10.6.5 Lannett Recent Development
10.7 Mylan
10.7.1 Mylan Company Information
10.7.2 Mylan Introduction and Business Overview
10.7.3 Mylan Drugs of UDCA Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Mylan Drugs of UDCA Products Offered
10.7.5 Mylan Recent Development
10.8 Bruschettini
10.8.1 Bruschettini Company Information
10.8.2 Bruschettini Introduction and Business Overview
10.8.3 Bruschettini Drugs of UDCA Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Bruschettini Drugs of UDCA Products Offered
10.8.5 Bruschettini Recent Development
10.9 Impax
10.9.1 Impax Company Information
10.9.2 Impax Introduction and Business Overview
10.9.3 Impax Drugs of UDCA Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Impax Drugs of UDCA Products Offered
10.9.5 Impax Recent Development
10.10 Shanghai Pharma
10.10.1 Shanghai Pharma Company Information
10.10.2 Shanghai Pharma Introduction and Business Overview
10.10.3 Shanghai Pharma Drugs of UDCA Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Shanghai Pharma Drugs of UDCA Products Offered
10.10.5 Shanghai Pharma Recent Development
10.11 Grindeks
10.11.1 Grindeks Company Information
10.11.2 Grindeks Introduction and Business Overview
10.11.3 Grindeks Drugs of UDCA Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Grindeks Drugs of UDCA Products Offered
10.11.5 Grindeks Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Drugs of UDCA Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Drugs of UDCA Industrial Chain Analysis
11.4 Drugs of UDCA Market Dynamics
11.4.1 Drugs of UDCA Industry Trends
11.4.2 Drugs of UDCA Market Drivers
11.4.3 Drugs of UDCA Market Challenges
11.4.4 Drugs of UDCA Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Drugs of UDCA Distributors
12.3 Drugs of UDCA Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
